Compare Enveric Biosciences Inc (ENVB) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Western Alliance Bancorporation — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Western Alliance Bancorporation trades at $84.03 (market cap $8.93B). The key difference: Western Alliance Bancorporation is far larger — about 1678.6× Enveric Biosciences Inc's market cap, and Western Alliance Bancorporation pays a 2.05% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WAL | |
|---|---|---|
Market Cap | $5.32M | $8.93B |
Sector | Health | Financials |
52-Week High | $17.40 | $96.08 |
52-Week Low | $1.28 | $66.70 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Western Alliance Bancorporation (WAL) trades at $83.33, up 3.7% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The stock shows solid fundamentals with a P/E of 9.52, net income margin of 25.63%, and a history of beating earnings estimates in recent quarters. Recent news highlights operational recognition, including being named Arizona's #1 Best Bank by Forbes in June 2026 and announcing a $0.42 dividend for H1-2026.
The outlook is positive given strong profitability, consistent earnings beats, and overwhelming analyst support (79% Buy ratings). Key risks include significant negative operating cash flow in 2025 (-$2.68B) and reliance on financing activities for liquidity. The stock trades below the consensus price target of $90.67, offering potential upside if the company can improve cash generation from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
